389 related articles for article (PubMed ID: 32735910)
1. JNK signaling contributes to skeletal muscle wasting and protein turnover in pancreatic cancer cachexia.
Mulder SE; Dasgupta A; King RJ; Abrego J; Attri KS; Murthy D; Shukla SK; Singh PK
Cancer Lett; 2020 Oct; 491():70-77. PubMed ID: 32735910
[TBL] [Abstract][Full Text] [Related]
2. Cryptotanshinone prevents muscle wasting in CT26-induced cancer cachexia through inhibiting STAT3 signaling pathway.
Chen L; Yang Q; Zhang H; Wan L; Xin B; Cao Y; Zhang J; Guo C
J Ethnopharmacol; 2020 Oct; 260():113066. PubMed ID: 32505837
[TBL] [Abstract][Full Text] [Related]
3. Valproic acid attenuates skeletal muscle wasting by inhibiting C/EBPβ-regulated atrogin1 expression in cancer cachexia.
Sun R; Zhang S; Hu W; Lu X; Lou N; Yang Z; Chen S; Zhang X; Yang H
Am J Physiol Cell Physiol; 2016 Jul; 311(1):C101-15. PubMed ID: 27122162
[TBL] [Abstract][Full Text] [Related]
4. Matrine improves skeletal muscle atrophy by inhibiting E3 ubiquitin ligases and activating the Akt/mTOR/FoxO3α signaling pathway in C2C12 myotubes and mice.
Chen L; Chen L; Wan L; Huo Y; Huang J; Li J; Lu J; Xin B; Yang Q; Guo C
Oncol Rep; 2019 Aug; 42(2):479-494. PubMed ID: 31233199
[TBL] [Abstract][Full Text] [Related]
5. Muscle-specific E3 ubiquitin ligases are involved in muscle atrophy of cancer cachexia: an in vitro and in vivo study.
Yuan L; Han J; Meng Q; Xi Q; Zhuang Q; Jiang Y; Han Y; Zhang B; Fang J; Wu G
Oncol Rep; 2015 May; 33(5):2261-8. PubMed ID: 25760630
[TBL] [Abstract][Full Text] [Related]
6. Selumetinib Attenuates Skeletal Muscle Wasting in Murine Cachexia Model through ERK Inhibition and AKT Activation.
Quan-Jun Y; Yan H; Yong-Long H; Li-Li W; Jie L; Jin-Lu H; Jin L; Peng-Guo C; Run G; Cheng G
Mol Cancer Ther; 2017 Feb; 16(2):334-343. PubMed ID: 27599525
[TBL] [Abstract][Full Text] [Related]
7. ZIP4 Promotes Muscle Wasting and Cachexia in Mice With Orthotopic Pancreatic Tumors by Stimulating RAB27B-Regulated Release of Extracellular Vesicles From Cancer Cells.
Yang J; Zhang Z; Zhang Y; Ni X; Zhang G; Cui X; Liu M; Xu C; Zhang Q; Zhu H; Yan J; Zhu VF; Luo Y; Hagan JP; Li Z; Fang J; Jatoi A; Fernandez-Zapico ME; Zheng L; Edil BH; Bronze MS; Houchen CW; Li YP; Li M
Gastroenterology; 2019 Feb; 156(3):722-734.e6. PubMed ID: 30342032
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of Stat3 activation suppresses caspase-3 and the ubiquitin-proteasome system, leading to preservation of muscle mass in cancer cachexia.
Silva KA; Dong J; Dong Y; Dong Y; Schor N; Tweardy DJ; Zhang L; Mitch WE
J Biol Chem; 2015 Apr; 290(17):11177-87. PubMed ID: 25787076
[TBL] [Abstract][Full Text] [Related]
9. Myostatin is a novel tumoral factor that induces cancer cachexia.
Lokireddy S; Wijesoma IW; Bonala S; Wei M; Sze SK; McFarlane C; Kambadur R; Sharma M
Biochem J; 2012 Aug; 446(1):23-36. PubMed ID: 22621320
[TBL] [Abstract][Full Text] [Related]
10. Group I Paks support muscle regeneration and counteract cancer-associated muscle atrophy.
Cerquone Perpetuini A; Re Cecconi AD; Chiappa M; Martinelli GB; Fuoco C; Desiderio G; Castagnoli L; Gargioli C; Piccirillo R; Cesareni G
J Cachexia Sarcopenia Muscle; 2018 Aug; 9(4):727-746. PubMed ID: 29781585
[TBL] [Abstract][Full Text] [Related]
11. Role of PARP activity in lung cancer-induced cachexia: Effects on muscle oxidative stress, proteolysis, anabolic markers, and phenotype.
Chacon-Cabrera A; Mateu-Jimenez M; Langohr K; Fermoselle C; García-Arumí E; Andreu AL; Yelamos J; Barreiro E
J Cell Physiol; 2017 Dec; 232(12):3744-3761. PubMed ID: 28177129
[TBL] [Abstract][Full Text] [Related]
12. The systemic activin response to pancreatic cancer: implications for effective cancer cachexia therapy.
Zhong X; Pons M; Poirier C; Jiang Y; Liu J; Sandusky GE; Shahda S; Nakeeb A; Schmidt CM; House MG; Ceppa EP; Zyromski NJ; Liu Y; Jiang G; Couch ME; Koniaris LG; Zimmers TA
J Cachexia Sarcopenia Muscle; 2019 Oct; 10(5):1083-1101. PubMed ID: 31286691
[TBL] [Abstract][Full Text] [Related]
13. Molecular and Physiological Evaluation of Pancreatic Cancer-Induced Cachexia.
Shukla SK; Dasgupta A; Mulder SE; Singh PK
Methods Mol Biol; 2019; 1882():321-333. PubMed ID: 30378066
[TBL] [Abstract][Full Text] [Related]
14. Targeted ablation of TRAF6 inhibits skeletal muscle wasting in mice.
Paul PK; Gupta SK; Bhatnagar S; Panguluri SK; Darnay BG; Choi Y; Kumar A
J Cell Biol; 2010 Dec; 191(7):1395-411. PubMed ID: 21187332
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms of skeletal muscle degradation and its therapy in cancer cachexia.
Melstrom LG; Melstrom KA; Ding XZ; Adrian TE
Histol Histopathol; 2007 Jul; 22(7):805-14. PubMed ID: 17455154
[TBL] [Abstract][Full Text] [Related]
16. Ursolic acid alleviates cancer cachexia by inhibiting STAT3 signaling pathways in C2C12 myotube and CT26 tumor-bearing mouse model.
Chen L; Chen Y; Wang M; Lai L; Zheng L; Lu H
Eur J Pharmacol; 2024 Apr; 969():176429. PubMed ID: 38423241
[TBL] [Abstract][Full Text] [Related]
17. Cucurbitacin IIb attenuates cancer cachexia induced skeletal muscle atrophy by regulating the IL-6/STAT3/FoxO signaling pathway.
Wang Y; Sun X; Yang Q; Guo C
Phytother Res; 2023 Aug; 37(8):3380-3393. PubMed ID: 37073890
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of heat shock protein (HSP) 90 reverses signal transducer and activator of transcription (STAT) 3-mediated muscle wasting in cancer cachexia mice.
Niu M; Song S; Su Z; Wei L; Li L; Pu W; Zhao C; Ding Y; Wang J; Cao W; Gao Q; Wang H
Br J Pharmacol; 2021 Nov; 178(22):4485-4500. PubMed ID: 34265073
[TBL] [Abstract][Full Text] [Related]
19. Macrophages potentiate STAT3 signaling in skeletal muscles and regulate pancreatic cancer cachexia.
Shukla SK; Markov SD; Attri KS; Vernucci E; King RJ; Dasgupta A; Grandgenett PM; Hollingsworth MA; Singh PK; Yu F; Mehla K
Cancer Lett; 2020 Aug; 484():29-39. PubMed ID: 32344015
[TBL] [Abstract][Full Text] [Related]
20. Tumor-derived IL-6 and trans-signaling among tumor, fat, and muscle mediate pancreatic cancer cachexia.
Rupert JE; Narasimhan A; Jengelley DHA; Jiang Y; Liu J; Au E; Silverman LM; Sandusky G; Bonetto A; Cao S; Lu X; O'Connell TM; Liu Y; Koniaris LG; Zimmers TA
J Exp Med; 2021 Jun; 218(6):. PubMed ID: 33851955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
